Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 20

NUZYRA: As First-line Therapy Targeted Patient Profiles CABP ABSSSI Alternative to fluoroquinolone + β-lactam allergic Prior C. difficile infection Suspected polymicrobial infection + β-lactam / sulfa allergic Renal insufficiency + SSRI